KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Current Taxes (2017 - 2025)

Sarepta Therapeutics has reported Current Taxes over the past 7 years, most recently at $9.1 million for Q3 2025.

  • For Q3 2025, Current Taxes changed N/A year-over-year to $9.1 million; the TTM value through Sep 2025 reached $9.1 million, changed N/A, while the annual FY2024 figure was $17.4 million, 26.33% up from the prior year.
  • Current Taxes for Q3 2025 was $9.1 million at Sarepta Therapeutics, down from $18.7 million in the prior quarter.
  • Over five years, Current Taxes peaked at $79.9 million in Q1 2025 and troughed at $216000.0 in Q4 2021.
  • A 5-year average of $19.6 million and a median of $16.7 million in 2023 define the central range for Current Taxes.
  • Biggest five-year swings in Current Taxes: soared 5696.76% in 2022 and later rose 9.94% in 2023.
  • Year by year, Current Taxes stood at $216000.0 in 2021, then soared by 5696.76% to $12.5 million in 2022, then rose by 9.94% to $13.8 million in 2023, then grew by 26.33% to $17.4 million in 2024, then crashed by 47.73% to $9.1 million in 2025.
  • Business Quant data shows Current Taxes for SRPT at $9.1 million in Q3 2025, $18.7 million in Q2 2025, and $79.9 million in Q1 2025.